Journal of the American Academy of Child and Adolescent Psychiatry
-
J Am Acad Child Adolesc Psychiatry · Jan 2012
Randomized Controlled Trial Multicenter Study Comparative StudyA controlled trial of extended-release guanfacine and psychostimulants for attention-deficit/hyperactivity disorder.
To examine efficacy, tolerability, and safety of guanfacine extended release (GXR; ≤4 mg/d) adjunctive to a long-acting psychostimulant for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children and adolescents 6 to 17 years of age with suboptimal, but partial, response to psychostimulant alone. ⋯ Morning or evening GXR administered adjunctively to a psychostimulant showed significantly greater improvement over placebo plus psychostimulant in ADHD symptoms and generated no new safety signals. Clinical trial registration information-Efficacy and Safety of SPD503 in Combination With Psychostimulants; http://www.clinicaltrials.gov; NCT00734578.